Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...
Novo Nordisk upgraded to Market Perform at Bernstein on valuation
As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...
Should You Buy the Dip in Novo Nordisk Stock Right Now?
What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
Bernstein upgrades Novo Nordisk (0QIU) to a Hold
Novo Nordisk (0QIU – Research Report) received a Hold rating and a DKK600.00 price target from Bernstein analyst Florent Cespedes today. The ...
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.
Morningstar4d
Novo Nordisk AS ADR NVO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioSpace21h
Novo Launches Citizen Petition to Block Compounded Victoza
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide.